CKR 334
Alternative Names: CKR-334Latest Information Update: 31 Jul 2023
Price :
$50 *
At a glance
- Originator CK Regeon
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action CXXC5 protein inhibitors; Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus; Non-alcoholic fatty liver disease; Obesity
Most Recent Events
- 24 Jul 2023 Preclinical trials in Diabetes mellitus in South Korea (PO) before July 2023 (CK Regeon pipeline, July 2023)
- 24 Jul 2023 Preclinical trials in Non-alcoholic fatty liver disease in South Korea (PO) before July 2023 (CK Regeon pipeline, July 2023)
- 24 Jul 2023 Preclinical trials in Obesity in South Korea (PO) before July 2023 (CK Regeon pipeline, July 2023)